Search for: [Abstract = "omplete planned treatment received, progression of the disease was observed in 43%, partial remission in 34% and stabilization in 23% of the patients. In NHL subgroup CR was obtained in 52%, PR in 14% and PD in 34% of patients. In 10 subjects progression of disease was observed. Mean time to progression was 11,5 months, in patients with partial remission \- 10,5 months, in patients with complete remission 16,4 months. Longer time to progression could be observed in subjects with complete remission. The treatment with 90Y\-DOTA TATE in patients with NETs did not result in significant nephrotoxicity and the decrease in CBC parameters was transient. In comparison to other methods of the treatment relatively high percentage of partial remission was obtained after completion of therapy. In NHL patients 3 and 4 grade of toxicity regarding CBC was also transient and the parameters normalised gradually in subsequent weeks after therapy. RIT proved to be safe method of therapy enabling complete remission achievement in most of the treated patients. According to presented results it seems that 90Y\-Ibritumomab tiuxetan therapy should be implemented in early stage of disease as the first line of the treatment to achieve high percentage of complete remissions and longer time to progression."]

Number of results: 1